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ABSTRACT
Forward Chemical Genetics Drug Screen Yields Novel Proteases and Proteolytic Inhibitors
of HGF‐induced Epithelial‐Mesenchymal Transition
Jeffrey Thomas Schuler
Department of Physiology and Developmental Biology, BYU
Master of Science
Hepatocyte Growth Factor (HGF)‐induced Epithelial‐Mesenchymal Transition (EMT) is a
complex cellular pathway that causes epithelial cell scattering by breaking cell‐cell contacts,
eliminating apical‐basal polarity, and replacing epithelial markers and characteristics with
mesenchymal markers. Early EMT events include a brief period of cell spreading, followed by
cell compaction and cell‐cell contact breaks. A forward chemical genetics drug screen of 50,000
unique compounds measuring HGF‐induced cell scattering identified 26 novel EMT inhibitors,
including 2 proteolytic inhibitors. Here, we show that B5500‐4, one of the EMT inhibitors from
the screen, blocks HGF‐induced EMT by a predicted blocking of the protease furin, in addition
to secondarily blocking Beta‐Secretase (BACE).
We also show that MMP‐12 and MMP‐9 are required for HGF‐induced EMT to progress.
MMP‐12 is required for cell contraction, and its inhibition produces a continuous cell spreading
phenotype.
We also demonstrate that both furin and BACE activity are required for HGF‐induced
EMT to proceed, but that they are involved in separate pathways. We show that BACE
inhibition leads to a failure of cell spreading in early EMT, and that EphA2 is a member of this
pathway. We also demonstrate that it is likely BACE2, and not BACE1 that is responsible for
early cell spreading. Furin is also required for HGF‐induced cell scattering, but does not play a
role in the cell spreading process. These findings highlight the importance of proteolytic activity
at the earliest stages of HGF‐induced EMT.
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CHAPTER 1: Introduction and Literature Review
An Overview of the Biological Uses of Epithelial‐Mesenchymal Transition
The development of most organ systems requires restructuring and reorganization of
embryonic cells into functional tissues through multiple stages of Epithelial‐mesenchymal
transition (EMT) and mesenchymal‐epithelial transition (MET) (Birchmeier 1996). Groups of
individual cells assemble into epithelial tissues by forming cell‐cell contacts with their neighbors
and establishing an apical‐basal polarity, which occurs through the sequential organization of
adherens junctions, tight junctions, and desmosomes (Barasch 2001). Additionally, gap
junctions between cells enable communication throughout the epithelial cell layer (Defamie
2014). Separation between epithelial sheets and adjacent tissues is maintained by the
formation of a basal lamina, a layer of extracellular matrix upon which epithelial sheets sit
(Barasch 2001). Mesenchymal cells, on the other hand, maintain minimal cell‐cell contacts,
invade through and within the extracellular matrix, and are typically found throughout
connective tissues below the epithelial layer and its basal lamina (Defamie 2014).
The transformation from epithelial to mesenchymal phenotype is a complex cellular
event characterized by the loss of cell‐cell junctions and apical‐basal polarity, and the
acquisition of mesenchymal characteristics and migratory abilities (Stoker 1985, Weidner 1991,
Bhargava 1992, Ridley 1995). Epithelial cells are induced to undergo EMT, or ‘scatter’ in the
case of cultured cells, by a variety of signaling and environmental factors, including HGF, VEGF,
EGF, TGF‐beta, Wnt, Notch, tissue wounding, and hypoxia (Ridley 1995, Morabito 2001, Kim
2002, Timmerman 2004, Saika 2003, Boyer 1992). EMT is induced by these different factors at
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some of the earliest stages of tissue organization during embryonic development (Kalcheim
2015).
Three distinct stages of EMT and MET are required for determining the final cell‐fates of
many specialized tissues, and are referred to as Primary, Secondary, and Tertiary EMT. The first
instances of EMT within the developing embryo are known as Primary EMT, and occur in most
multicellular organismal development (Kalcheim 2015). Examples include EMT events during
mammalian implantation, during gastrulation in metazoans, and during neural crest
development in vertebrates. The formation of the parietal endoderm is one of the first EMT
events in embryonic development. Cells from the inner cell mass break cell‐cell contacts,
migrate through the primitive endoderm, and relocate along the inner blastocyst walls to form
the parietal endoderm (Kalcheim 2015). Mesoderm formation also requires EMT. In this process
cells invade through the primary streak and reorganize into the mesodermal tissue. EMT is also
observed throughout later development. Somites undergo EMT during the vertebral
development of the embryo. Several rounds of EMT and MET occur during heart valve
development (Barasch 2001).
The Role of EMT in Disease Progression
While epithelial cell scattering is required for embryonic development, tissue
maintenance, and wound healing, its inappropriate activation contributes pathologically to
fibrosis, Crohn’s disease, cataract formation, and cancer metastasis (Bataille 2008, Kalluri 2003,
de Longh 2005, Ruiz 1996).
Cancer and some other disease types misuse EMT to form dangerous and life‐
threatening phenotypes. Cancer cells often hijack EMT pathways, leading to increased cell
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scattering and mesenchymal characteristics. Cancer cells undergoing EMT produce proteolytic
enzymes that degrade the basement membrane, allowing for individual cells to locally invade
and migrate to distant tissues. Mesenchymal‐epithelial transition then occurs, resulting in the
formation of distant metastases (Polyak 2009). Accompanying EMT during cancer progression
are a variety of changes to cellular behavior, including resistance to apoptosis, enhanced
survival, genome instability, and resistance to chemotherapy, all of which affect disease
progression and prognosis (Blick 2008, Kalluri 2009, Polyak 2009). It is particularly important to
figure out the best methods of inhibiting the EMT program from progressing in cancer, as
metastatic cancer is much more difficult to treat than non‐metastatic cancer.
The Role of HGF and the c‐Met Pathway in Driving the EMT Program
Hepatocyte Growth Factor (HGF) and its target, the c‐Met receptor tyrosine kinase are
of particular interest in cancer research. HGF‐induced EMT initiates a complex and specific
program referred to as invasive growth, and is most often characterized by the dissociation of
cell‐cell junctions via decreased membrane‐localized E‐cadherin, and increased N‐cadherin
expression. Downstream activation of the RAS, PI3K, STAT, Notch, and beta‐catenin signaling
pathways are required for HGF‐induced EMT to progress (O’Brien 2004, Marshall 1995, Graziani
1991, Boccaccio 1998, Monga 2002). The switch from epithelial to mesenchymal states is
driven by activation of key transcription factors SNAIL, SLUG, TWIST, and ZEB1/2 (Rodriguez‐
Paredes 2011). In carcinomas, aberrant activation of the c‐Met pathway leads to more
metastatic behavior in cancers and to a poorer prognosis in multiple cancer types (Baschnagel
2014, Yoshinao 2000, Masuya 2004).
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Epigenetic changes can also regulate EMT progression. Cell scattering can be initiated
when mesenchymal genes and their promoter sites undergo H3 acetylation or H3K4
trimethylation, or when there is hypermethylation of their repressor sites (Rodriguez‐Paredes
2011, Ehrlich 2009, Ehrlich 2002). The miRNA‐200 and miRNA‐205 families have specifically
been linked to the regulation of the EMT program, which in turn are regulated by histone
modification (Fullgrabe 2011). These and many other epigenetic factors have shown
pronounced effects in the regulation of the cell scattering program.
In addition to intracellular signaling cascades and regulatory networks, a variety of
extracellular environmental cues contribute to the HGF‐induced cell scattering event. Cell‐
substrate stiffness can directly influence the ability of epithelial cells to undergo HGF‐induced
EMT (Hoj 2014); increasing the pliability of the surface substratum reduces cell‐substrate
tension, which in turn reduces HGF‐induced cell scattering (Hoj 2014). Increases in cell‐
substrate tension also leads to increased nuclear localization of YAP/TAZ, which act as
mechanotransduction sensors and mediators that respond to tension changes in the cellular
microenvironment (Sirio 2011).
Other signaling pathways can also interact with and affect the progression of HGF‐
induced cell scattering. TGF‐beta can enhance HGF‐induced EMT, and has a chemotaxic effect
on scattering cells. VEGF and TGF‐beta act competitively to enhance HGF, and VEGF will
neutralize the additive scattering of TGF‐beta (Chung 2011). The crosstalk that exists between
major signaling pathways and the c‐Met pathway serves to underscore the complexity of the
scattering pathway, and emphasizes the need to further study this cellular event in greater
detail.
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The Role of Proteases in EMT and HGF‐pathway Programs
Among the earliest changes in cell behavior during EMT initiation includes proteolytic
activation and deactivation (Tervonen 2015, Craig 2015, Ha 2015, Gray 2014). Cell surface
serine protease Hepsin activity increases downregulates HGF activator inhibitor type 1 (HAI‐1),
increasing HGF‐pathway activation and EMT progression (Tervonen 2015). Chemical inhibition
of matrix metalloproteinases 2/9 by Sorafineb inhibits c‐Met and MEK/ERK pathways, leading to
decreased migration and invasion of hepatocellular carcinoma cells (Ha 2015). Additionally,
matrix metalloproteinases 3, 7, and 8 have been implicated in EMT progression in patients with
idiopathic pulmonary fibrosis (Craig 2015). Additionally, type‐II transmembrane serine protease
matriptase inhibition leads to a failure of HGF‐dependent EMT in MDCK cells (Gray 2014).
Increasing numbers of proteases are being found to regulate EMT progression; however,
the roles of many of these proteases have yet to be fully understood (Tervonen 2015).
Additionally, many additional proteases may yet hold undiscovered roles in c‐Met pathway and
EMT regulation.
A High‐Throughput EMT Assay Yields Novel EMT Inhibitors
While traditional research methods have provided valuable insights into
signaling pathways and their mechanics, a forward chemical genetics screen provides a fresh
perspective of the c‐Met pathway by allowing for the simultaneous discovery of novel
molecular components and new drug inhibitors of HGF‐induced EMT. Pharmacologically
inhibiting the scattering phenotype not only provides the opportunity to further understand the
molecular components of the pathways involved, but can also reveal the therapeutic potential
and clinical relevance of the novel inhibitors in the treatment of several human diseases,
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including and especially cancer metastasis (Kubinyi 2002, Russel 2004, Carlson 2012, Cornelius
2011) .
The forward chemical genetic screen stands as a unique method for identifying novel
molecular components in a pathway, and provides several key advantages and disadvantages.
In this approach, molecules from large chemical libraries are assessed for biological activity in a
high‐throughput and high content assay system that measures the biological output of some
cellular process or pathway. Compounds identified in screening are expected to target cellular
machinery required for the cellular process or pathway of interest. The drawback to this
method is that once a drug candidate is identified, further work must be done to identify the
molecular target of the compound.
In a prior publication, we reported a drug screen of 50,000 distinct chemical compounds
in a high throughput assay testing inhibition of cell scattering and reported those with known
biological activity, which highlights how this approach works (Langford 2012). In our screening
assay, MDCK cells are seeded on a 96‐well trans‐well plate and induced to undergo EMT with
HGF. The screen yielded 20 biologically relevant small chemical inhibitors of HGF‐induced cell
scattering out of the compound library. One of these 20 chemical scaffolds is a neuronal
calcium channel blocker (Langford 2012). Subsequent experiments designed to understand
why a calcium channel blocker would prevent EMT revealed that a calcium influx follows HGF
stimulation and is required for progression of EMT.
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CHAPTER 2: Results
HGF Causes Cell Surface Area Spreading, then Contraction in MDCK Cells
The cellular events associated with HGF‐induced epithelial scattering of MDCK cells have
been carefully characterized previously (Sperry 2010). Here we repeat the results of Sperry et
al. (Sperry 2010) by seeding MDCK cells into collagen‐coated imaging dishes. After 24‐48 hours,
small colonies of MDCK cells were picked for brightfield live cell imaging before initiation of
imaging. To observe epithelial scattering, cultures were stimulated with HGF immediately prior
to initiation of imaging. For each experiment, we performed imaging on a minimum of 15
colonies in order that we might observe reproducible effects throughout each culture. Further,
experiments were reproduced 3 times to highlight any differences between independent
experiments. Thus, for each experimental condition, we analyzed at least 3x colonies of MDCK
cells. Our results show that MDCK cell colonies stimulated with HGF undergo cell spreading,
which occurs within the first two hours after HGF treatment (Fig. 2.1A). To quantitatively
define this cell spreading, we measured to amount of the culture dish covered by colonies of
MDCK cells during imaging and normalized this area to the number of cells in each colony. This
quantitation shows that MDCK cell contact with the collagen substrate increases by some 44%
within the first two hours (Fig. 2.1A, C). Following the two hour cell spreading phase, HGF‐
induced MDCK cell colonies begin a period of contraction that lasts the following 6 hours.
During contraction, cells initiate migration and rupture cell‐cell adhesions. According to our
quantitation of cell area during imaging, MDCK cell surface area returns to levels observed prior
to responding to HGF stimulation and may contract even further, particularly as cell‐cell
contacts break. Unstimulated MDCK cells show limited changes in cell spreading, not
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contractile activity, limited migration, and only slow repositioning within the colony (Fig. 2.1B).
While we do see unstimulated colonies grow in size, there is no net gain in cell area as most of
the change in size is accounted for by cell division.
Identification and Chemical Optimization of B5500
From the 50,000 chemical compound pilot screen, 20 biologically active EMT blockers
were identified, including one nicotinamide derivative, N‐(5‐iodo‐6‐methyl‐2‐pyridinyl)‐3‐
nitrobenzamide (B5500) (Fig. 2.2A). Of these, 11 bear an unknown mechanism of action.
We reasoned that molecules of high interest would affect cellular machinery required
for EMT in multiple model systems, so we sought to assess which molecules might affect EMT in
another system unrelated to MDCK cells. Further, the ability to use human cell lines, as
opposed to canine MDCK cells, would allow us to employ a number of assay systems that rely
on human cell lines and that could provide key information about the molecular target of our
compounds. We therefore assessed compounds that are active in our screening assay for the
activity in blocking invasive behavior of the trophoblast cell line Sw71. Screening these 11
compounds through a cell invasion assay of SW71 human trophoblast cells in a collagen matrix
again demonstrated their ability to block EMT from progressing, demonstrating a molecular
mechanism that is present in multiple organism and tissue types (in this case, canine kidney and
human trophoblast cell lines) (Fig. 2.2C). Of the 11 EMT inhibitors tested in the SW71 invasion
assay, 7 compounds showing statistically significant reduction of invasion, including B5500. 10
uM B5500 inhibited SW71 invasion by 33% of the DMSO control trial.
We sought to determine which of these molecules would be the most likely to reveal
novel biology about epithelial scattering. One issue with our overall approach is that
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microtubules are required for epithelial scattering of MDCK cells in response to HGF. Since
microtubule‐targeting agents are found with high frequency in phenotypic assays, we sought to
avoid working with compounds that inhibit HGF‐induced EMT by targeting the microtubule
cytoskeleton. In order to understand which molecules target microtubules, we assessed
compounds from our original screen in proliferation assays using the NCI‐60 panel of cancer cell
lines. Since microtubules are required for cell division, compounds bearing microtubule
targeting activity would inhibit cell proliferation of the majority of cell lines in this panel.
Inhibition of a subset of cell lines would instead suggest the targeting of a protein required for
the growth of some cells, revealing a potential mechanism of action for the compound under
question. We found that only B5500 had no general effects on cell growth in these proliferation
assays, meaning it is the only compound that certainly works independently of a microtubule‐
based mechanism.
We sought to optimize the specific activity of B5500 in arresting HGF‐induced epithelial
scattering. We generated 49 chemical derivatives of B5500 and assessed them in our original
screening assay, yielding three analogs with increased activity (Fig. 2.2D). For each of these
new derivatives, the activity in affecting scattering or migration was compared to anti‐
proliferative activity. B5500‐25 and B5500‐26 show potent cell growth inhibition that
accompanies their activity in the HGF‐induced EMT assay. Another compound, N‐(5‐bromo‐6‐
methyl‐2‐pyridinyl)‐pyrimidine‐5‐carboxamide (B5500‐4) (Fig. 2.2B), affects cell proliferation
only at high concentrations, but retains significant activity in blocking HGF‐induced EMT. This
compound likely affects HGF‐induced EMT completely independently of microtubules. Since it is

9

more potent than B5500, we sought to use this molecule for our subsequent target
identification experiments.
In order to confirm that B5500‐4 affects scattering behavior of human cells and to
determine its potency, we measured its activity in invasion assays using SW71 cells at
decreasing concentrations. We found that B5500‐4 does in fact block EMT and invasion in this
system and does so with an IC‐50 of ~27 nM (Fig. 2.2B).
B5500‐4 Target Identification
We initially sought to identify a target pathway for B5500 and B5500‐4 by assessing the
readout of compound treatment in a series of cell culture systems in which inflammatory
biomarker expression is analyzed. This so‐called BIO‐Map system consists of primary human
cells that are grown in culture alone or in combination, then activated to generate an
inflammatory response. In total, 12 different culture models were used and expression of a
total of >70 inflammatory markers were analyzed. The value of this system is that inhibition of a
signaling pathway will give a predictable readout that will be comparable to that generated
with inhibitors of known pathway components. As such, the BIO‐Map system is a powerful
approach to identifying the target of a small molecule inhibitor of unknown mechanism, at least
at the pathway level. However, no significant changes in the expression of any inflammatory
markers were associated with B5500‐4 treatment in this system (Fig. 2.3), suggesting that this
molecule does not target signal transduction machinery.
Additionally, B5500 was assessed for its activity in blocking the activity of protein
kinases with a panel of 230 kinases. B5500 was not active against any kinases tested (Fig. 2.4).
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This compound is not a kinase inhibitor, as we might expect from the lack of a discernable
readout in the BIO‐Map system.
To determine what effects B5500‐4 had on more classic EMT markers, we performed
western blots on e‐Cadherin (E‐cad), SNAIL, and SLUG in several human cancer cell lines (A549,
Psn‐1, and Panc‐1). A549, a human lung cancer cell line, maintains many epithelial
characteristics, including high expression of E‐cad, and low expression of mesenchymal markers
SNAIL and SLUG. Interestingly, the B5500‐4‐treated cell lines show no statistically significant
change in E‐cad, SNAIL, or SLUG protein levels in cancer cell lines A549, Psn‐1, and Panc‐1 (Fig.
2.5A). This finding suggests that B5500‐4 does not act by increasing epithelial characteristics
within cells (A549), nor by decreasing mesenchymal characteristics (Psn‐1, Panc‐1). This does
not rule out, however, that B5500‐4 could act via preventing the transition from epithelial to
mesenchymal states.
In order to identify any changes in gene expression caused by B5500‐4, we performed a
qPCR assay of 384 genes known to be involved in the regulation of EMT, extracellular matrix,
cytoskeleton (Fig. 2.6A‐D). SW71 cell samples were induced with B5500‐4 or DMSO (control)
for 24 hours, and cDNA samples were produced from harvested mRNA extracts. The cDNA
samples were run through the PCR plates, and the differential expression of various genes in
cells treated with B5500‐4 or DMSO compared. Several genes demonstrated large changes in
expression with B5500‐4 treatment, including and especially Col4A2 (1.05x104 fold change),
MMP‐12 (‐7.37x106 fold change), and mTOR (‐2.22x103 fold change) (Fig. 2.6A‐B).
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The Functional Requirement of MMPs in HGF‐induced Epithelial Cell Scattering
The changes in expression of MMP‐12 and of extracellular matrix in cells treated with
B5500‐4 suggest a possible role for cell surface proteases in the HGF pathway. The chemical
structure of B5500‐4 is also suggestive of binding within a proteolytic binding pocket, as the
central amide bond of the linker region closely resembles the peptide bind of an amino acid
chain (Fig. 2.2B). We hypothesized that B5500‐4 might be a protease inhibitor and specifically
target proteases in the MMP family. MMPs have already been implicated in EMT progression
and cancer metastasis, but the roles of MMP‐12 and MMP‐9 have yet to be fully characterized
in the context of epithelial cell scattering, cell spreading, and cell contraction (Craig 2015, Ha
2015).
In order to determine whether matrix metalloproteinases are required for HGF‐induced
EMT, inhibitors of proteases MMP‐12 and MMP‐9 were used to treat MDCK cells prior to
induction of scattering with HGF.
Chemical inhibition of MMP‐9 by Ilomastat of HGF‐induced MDCK cells blocks EMT (Fig.
2.7C). Neither cell spreading nor cell compaction occurs (Fig. 2.7E), indicating an unknown role
for MMP9 within the c‐Met cell scattering program. It is possible that MMP9 is required for
both cellular processes, or that its role precedes cell spreading and contraction.
MDCK cells treated with Marimastat (a blocker of MMP‐12) fail to scatter after HGF
stimulation (Fig. 2.7). While spreading is observed, it is drastically slowed. MDCK colonies
treated with Marimistat take 8 hours to reach the extent of maximal spreading observed in
control MDCK cells, which occurs in 2 hours (Fig. 2.7E). Additionally, no cell compaction is
observed for the duration of the experiment. This suggests that MMP-12 must be required
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for activation of the cell compaction program, but it remains unclear how MMP-12 inhibition
alters the time-frame and rate of cell spreading.
BACE is Required for Epithelial Cell Spreading in Early HGF‐induced EMT; Furin is Required for
Epithelial Cell Scattering, but Not Y‐secretase
We sought to test whether B5500 or B5500‐4 are inhibitors of matrix
metalloproteinases. Biochemical assays measuring the activity of different MMPs were
performed in the presence of a series of concentration of B5500. We tested several MMP
family members, including MMP 1‐3, 7‐10, and 12‐14. None of these proteases demonstrated
any reduction in activity at even the highest concentration (10uM) of B5500. Despite that
MMPs are indeed required for HGF‐induced epithelial scattering of MDCK cells, B5500 does
not prevent scattering by targeting MMPs.
In order to test whether the molecular target(s) of B5500‐4 included any other
proteases during EMT, a collaborator conducted molecular modeling experiment to measure
B5500‐4 binding affinity cell surface proteases (furin and beta‐secretase (BACE). In both cases,
B5500‐4 was expected to bind the active site of these proteases. We therefore determined to
test the role of these proteases in HGF‐induced epithelial scattering.
MDCK cells were seeded onto collagen‐coated imaging plates, treated with appropriate
inhibitor, stimulated to undergo epithelial scattering with HGF treatment, and subjected to live
cell imaging (Fig. 2.8). Darunavir (furin chemical inhibitor) treatment resulted in a failure of
epithelial cell scattering, suggesting a role for furin in the HGF pathway (Fig. 2.8A). Neither cell
spreading nor cell contraction occurs in furin-inhibited MDCK cells during HGF stimulation,
especially when compared with HGF-control MDCK cells (Fig. 2.1).
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Chemical inhibition of Y‐secretase proved to be cytotoxic; cell die 6 hours after
treatment (Fig. 2.8B), suggesting an important survival role for Y‐secretase, one that acts
independently of the c‐Met pathway.
MDCK cells treated with BACE inhibitor fail to undergo normal HGF‐induced scattering.
These cells showed undergo a cell compaction without undergoing any cell spreading. No effect
of BACE inhibitor is observed in MDCK cells that have not been stimulated with HGF (Fig. 2.9A‐
B). The compaction observed in BACE‐treated cells parallels cell compaction in control cells
treated with HGF after spreading has occurred (Fig. 2.9B). These results suggest a role for
BACE in the HGF pathway through regulating cell spreading, but not in cell compaction.
Summary of Novel Proteases Involved in HGF‐pathway
An illustration provides a graphical summary of the roles of the tested proteases within
the c‐Met pathway (Fig. 2.10). When induced with HGF, MDCK cells begin a cell spreading
phase, which requires BACE. After 2 hours of spreading, the MDCK cells undergo a cell
contraction phase, which requires MMP12. Regulation of both of these processes likely
requires MMP9 and furin, but not Y‐secretase, which activity is likely required for cell survival.
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CHAPTER 3: Discussion
Cellular Mechanics of Early EMT
Consistent with earlier reports, we have shown that MDCK cells undergo HGF‐induced
epithelial cell scattering in a two‐phase process, beginning with an early phase of cell spreading
and followed by a later cell contraction phase. It is during the cell contraction phase that cell‐
cell contacts are broken and cells fully separate from their neighbors, allowing for formerly
epithelial cells to migrate and invade as individual, solitary mesenchymal cells.
Whether cell‐cell contacts become weakened during early epithelial scattering, such as
during the early cell spreading phase, remains an open question. The current thinking of the
field, though in flux, is that forces coming from migration or other actomyosin‐based contractile
processes are sufficient to rupture fully cell‐cell junctions without any prior changes to the
molecular architecture of the junction. In support of this, it appears that reduction in and
restoration of cellular contractility is enough to rupture cell‐cell contacts (Hoj 2014), indicating
that contractile forces alone are enough to rupture cell‐cell junctions. However, our prior work
show that exogenous expression of a ‘constitutively active’ fragment of the cytoskeleton‐
membrane linker protein, zyxin, results in an inability of cells to detach from each other during
epithelial scattering and results in cells that attempt to migrate while maintaining long tethers
to other cells (Sperry 2011). A resolution to this controversy is that contractile forces are likely
sufficient to drive cell‐cell detachment during HGF‐induced epithelial scattering, but that this
must be preceded by a relaxation of actomyosin‐based tensin forces that results in uncoupling
of cadherin cell‐cell adhesion receptors from the actin binding protein, alpha‐catenin, which
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form cadherin‐catenin‐actin complexes that link cell contacts to the actin cytoskeleton only
when under tension.
Our focus here has been to study and characterize the mechanics of this two phase
process. A powerful approach to understanding complex cellular processes in tissue culture
models, particularly for identifying cellular components required for the process under
question, is to employ unbiased chemical screening. We follow up on a high content phenotypic
screening approach that led us to a molecule with activity that is highly specific for blocking
HGF‐induced epithelial scattering and not cell division processes (a sign of microtubule
targeting).
B5500‐4 Characteristics and Mechanism
We optimized the original molecule identified in screening to increase the specificity for
inhibition of HGF‐induced epithelial scattering over anti‐proliferative activity, yielding the
molecule B5500‐4. This molecule inhibits HGF‐induced epithelial scattering in MDCK cells in the
original screening assay and blocks invasion of trophoblast cells with high potency.
Interestingly, it produces no effect on the expression of classic EMT markers, such an E‐ and N‐
cadherin, SLUG, and SNAIL, when used to treat mesenchymal cancer cells. While we have not
looked at whether B5500‐4 can prevent expression of mesenchymal markers in cells
undergoing epithelial scattering, our results suggest that inhibition of the target of our
compound cannot induce a reversion to an epithelial phenotype among cells that are already
mesenchymal.
Defining the mechanism of action of B5500 and B5500‐4 has proven to be a major
challenge, as is often the case for molecules identified in phenotypic high content screens.
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Assessment for activity in blocking the activity of a large panel of 230 kinases shows that these
compounds are not kinase inhibitors. We then turned to another high content screen where
inhibition of different signaling pathways has specific and recognizable readout patterns, the
so‐called BioMAP screen. Even here the results are negative and suggest that the target of
these compounds is not a signaling molecule.
Clues to the identity of the molecular target were first obtained in assessing changes in
expression patterns resulting from B5500‐4 treatment using a PCR array system, where the
most affected genes are an extracellular matrix protein and a matrix metalloproteinase. In fact,
recent findings from this lab have shown that characteristics of the extracellular matrix,
including its substrate stiffness, can have dramatic effects on the ability of MDCK cells to
migrate while undergoing HGF induction (Hoj 2014) and support a role for matrix remodeling
enzymes like MMPs in HGF‐induced epithelial scattering.
MMP Function in the Mechanics of HGF‐induced Epithelial Scattering
The MMP proteins MMP‐12 and MMP‐9 had both been shown in previous studies to be
involved in epithelial cell scattering, though not directly in response to HGF [40]. While our
qPCR assay indicates that MMP‐12 might be a target of B5500‐4 and is thus required for
epithelial cell scattering, we also assessed other MMP proteins for which there are readily
available inhibitors. Our time‐lapse microscopy of epithelial scattering of MDCK cells in the
presence of Marimastat and Ilomastat, chemical inhibitors of MMP‐12 and MMP‐9,
respectively, demonstrates that MMP‐9 and ‐12 are both required for epithelial cell scattering
in MDCK cells. More interesting is that MMP‐12 inhibition blocked the cell contraction phase
without affecting the cell spreading phase. MMP‐9, in contrast, inhibited both cell spreading
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and cell contraction phases of the cell scattering program, suggesting a molecular target
upstream and required for both programs in the scattering pathway.
Furin and BACE in HGF‐induced Epithelial Cell Scattering
While MMP‐9 and ‐12 were shown to be required for epithelial scattering, biochemical
assays reveal that B5500 is not an inhibitor of matrix metalloproteinases. Clues as to its
mechanism came from docking studies performed by a collaborator in silico and suggested that
B5500 and B5500‐4 bind the active sites of the surface proteases furin and BACE. To our
knowledge, a role for either protease in HGF‐induced epithelial scattering has not been
reported. BACE is produced as an inactive proenzyme protease and requires proteolytic
processing to become an active BACE protease (Creemers 2001). Interestingly, it is furin that
has been reported to mediate BACE processing (Creemers 2001). Treating MDCK cells with
inhibitors of these proteases and examining the impact of epithelial scattering reveals that both
are required, though the effect of inhibition of each protease is distinct. And since furin is one
of the major proteases to convert pro‐BACE to BACE, it was assumed that both would be
involved in the same pathway. The findings that BACE inhibition causes an HGF‐dependent cell
contraction response in MDCK cells, whereas furin does not, went against our hypothesis. We
had hypothesized that the inhibition of either protease would produce a similar cellular effect,
and yet it was the opposite that proved true. It became apparent that while furin may be
responsible for pro‐BACE cleavage, this certainly wasn’t the method of BACE activation involved
in the c‐Met pathway.
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CHAPTER 4: Methods and Protocols
Immunofluorescence Assays
Showing alterations to actin rearrangement via Frost‐100 were demonstrated using
immunofluorescence assays. MDCK cells plated for 24‐hours onto collagen‐coated coverslips
were induced with HGF and either B5500‐4, B5500, or DMSO (control). After a 24 hour
incubation period, cells were fixed via paraformaldehyde, and stained with phalloidin, anti‐
BACE, or anti‐EphA2 for subsequent imaging.
EMT Migration Assays
EMT assays were performed to quantify the anti‐scattering effects of B5500 and B5500‐
4. MDCK cells were plated onto trans‐well plates and left to incubate for 24 hours. At 24 hours,
the cells were induced with both HGF and either B5500‐4, B5500, or DMSO (control) at a variety
of concentrations (10 uM, 1 uM, 0.1 uM, 0.01 uM) and given an additional 24 hours to migrate
through the membrane. Cells were fixed via paraformaldehyde, and stained with crystal violet
stain. Fixed cells on the upper membrane surface were wiped away with cotton swabbing,
leaving only migrated cells on the bottom of the transwell filter membrane. The wells were
imaged and quantified using the SpotDenso tool on the Fluorchem Analysis program.
SW71 Cell Invasion Assay
The invasion assay measures the amount of cellular invasion colonies of cells undergo,
which in part relies on the ability of the cells to undergo EMT. Matrigel solution was poured
into a bottom well of a transmembrane system, on top of a thin‐film membrane and allowed
time to congeal. SW71 cells were seeded into the plate’s top chamber and starved of Fetal
Bovine Serum (FBS). A FBS gradient was created by adding a 5% FBS solution in the bottom
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well. The FBS acted as a chemoattractant to the FBS‐starved cells, initiating invasion down
through the matrigel. B5500‐4 and B5500 were added at increasing concentrations (10 uM, 1
uM, 0.1 uM, 0.01 uM) to the top well at the same time as the introduction of the FBS
gradient. A 24 hour incubation period was allowed for the cells to invade. Cells were then fixed
and stained with a Dissociation solution, and the bottom membrane was extracted and used to
generate a cell count for the invaded cells.
Time‐lapse Live‐cell Microscopy
MDCK cells seeded onto collagen‐coated Delta‐T movie dishes for 24 hours will be
induced with Frost‐100 at 10 uM, followed shortly by HGF. Single‐frame images will be taken at
multiple time points (every 2 minutes for 13 hours) and stitched together into a time‐lapse
movie using Slidebook software. Comparing Frost‐100 induced MDCK cells to DMSO control
MDCK cells will reveal the effects that Frost‐100 have on inhibiting migratory behavior.
Western Blot
Western blot of classic EMT protein markers‐‐E‐cadherin, N‐cadherin, Slug, and Snail‐‐
were performed to quantify the changes to the epithelial state of the target cells induced with
Frost‐100. MDCK cells were seeded for 24 hours and subsequently induced with HGF and
increasing concentrations of B5500‐4 or B5500 (10 uM, 1 uM, 0.1 uM, 0.01 uM). At 24 hours
after induction, cells were lysed using a cell lysis buffer containing 2‐mercaptoethanol and
protease inhibitors, and the cytosolic contents were collected and isolated via centrifugation. A
Bradford assay was performed on each of the cell lysate samples to equalize relative protein
concentrations, which was run through an SDS‐PAGE gel, and transferred to a nitrocellulose
membrane. The membrane was incubated with either anti‐e‐cadherin antibodies, anti‐n‐
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cadherin antibodies, anti‐Slug antibodies, or anti‐Snail primary antibodies followed by
secondary antibodies. Final blot images were then developed using the enhanced
chemiluminescence (ECL) detection system. The same membranes were also developed in an
anti‐β‐actin primary antibody (mouse), followed by anti‐mouse secondary antibodies in a
subsequent blot to provide an internal control. Quantification of the blots were obtained using
the spot‐denso analysis tool on the developed X‐ray films as a part of the Fluorchem SP imaging
system.
qPCR Array
Human trophoblast SW71 cells were cultured for 24 hours and then induced with 5 uM
B5500‐4 or with DMSO (control). After an additional 24 hour incubation time, the cells were
harvested and the RNA extracted using a Qiagen RNA extraction kit. The RNA samples were
equalized via Nanodrop spectrophotometry, and reverse‐transcribed into cDNA using the
Invitrogen Superscript II Reverse Transcriptase kit. The cDNA was added to SYBR Mastermix,
aliquotted into the PCR array plate, and run through a Qiagen thermocycler for 50 cycles,
according to kit specifications. The Frost‐100 and DMSO cDNA samples were compared to each
other in terms of number of cycles needed to reach an arbitrary threshold, which assigned each
trial a raw score, and gave an indication to the relative amounts of RNA from each sample and
the fold‐change between the two samples. Individual genes with the highest fold‐change in
expression were repeated in multiplicates to confirm the change in expression.
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GLISA Assay
A specific type of ELISA assay—the GLISA assay—was performed to measure ATP‐bound
proteins of interest, showing the effects of B5500‐4 on the levels of the specific proteins in their
activation state. SW71 cells were seeded for 24 hours and subsequently induced with B5500‐4
at a variety of concentrations (10 uM, 1 uM, 0.1 uM, 0.01 uM) for an additional 24 hours. Cells
were harvested with a cell lysis buffer containing 2‐mercaptoethanol and protease inhibitors,
centrifuged, and snap frozen in liquid nitrogen. Equalized protein samples‐‐measured via
Bradford assay—were then added to each well containing the GLISA substrates. After
incubation for 1 hour, lysate contents were discarded, and primary antibody solution was
added and allowed to incubate for 30 minutes. Primary antibody solution was discarded and
replaced with a secondary antibody solution, and incubated for 1 hour. The wells were rinsed
and fixing reagent was added and allowed to incubate for 15 minutes. The freezing reagent
was added and the wells are imaged and quantified using spectrophotometry.
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Figure 2.1: HGF‐induced EMT Includes Phase of Cell Spreading, Followed by Phase of Cell
Contraction. (A) MDCK cell time‐lapse microscopy of +/‐HGF treatment reveals cell scattering
events. (B) Graph of cell surface area over time. HGF‐treated cells increase surface area by
44% within first two hours, followed by cell contraction phase, when cells break cell‐cell
contacts and begin scattering.
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Figure 2.2: Characterization and Optimization of B5500. (A) Chemical structure of B5500. (B)
Chemical structure of B5500‐4. (C) SW71 cell invasion assay. SW71 cells were induced to
invade through 3D collagen matrix onto a transwell membrane, towards 10% FBS
chemoattractant. Tested compounds had final concentration of 10 uM. (D) Structure‐activity
relationship assay of B5500 and chemical derivatives. Left‐side and right‐side variations in the
table axes represent chemical compound changes made to the B5500 scaffold. 49 derivatives
were tested at a final concentration of 10 uM. Cell growth inhibition and migration inhibition of
most potent compounds included in table.
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Figure 2.3: Inflammation Assay Reveals No Significant Change in Inflammatory Marker
Expression. 12 cell lines were induced with B5500‐4 at several concentrations (10 uM, 3.33 uM,
1.11 uM, 37 nM) for 24 hrs and expression of a listed of inflammatory markers were measured.
Markers revealed change beyond allowed standard error (gray zones) were noted to yield
extremely small and insignificant changes from B5500‐4 treatment.
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Figure 2.4: Kinase Screen of B5500 Does Not Block Kinases in Kinase Screen. B5500 was tested
for effects on activity levels of a total of 230 kinases. Raw scores were generated from screen
data, with 100 indicating a 100% normal level of kinase activity. B5500 does not significantly
alter any of the 230 kinases screened.
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Figure 2.4 (continued): Kinase Screen of B5500 Does Not Block Kinases in Kinase Screen. B5500
was tested for effects on activity levels of a total of 230 kinases. Raw scores were generated
from screen data, with 100 indicating a 100% normal level of kinase activity. B5500 does not
significantly alter any of the 230 kinases screened.
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Figure 2.5: B5500‐4 Does Not Alter Levels of Classic EMT Markers. (A) Western blot of EMT
markers in human cancer cell lines with addition of B5500‐4 or DMSO. A549, Psn‐1 and Panc‐1
cells lines were tested for changes in expression in e‐Cadherin, SLUG, and Snail. (B) SW71 cell
invasion assay of B5500‐4. Dosage curve yielded IC‐50 of ~27 nM.
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Figure 2.6: qPCR Array Results Indicate Fold‐increase of Select Genes. Genes related to (A)
EMT, (B) ECM (C) cytoskeleton, and (D) mTOR pathway were tested. mRNA from SW71 cells
induced with either DMSO or B5500‐4 (10 uM) for 24 hrs was extracted, converted to cDNA,
and run through qPCR assay. Genes of significant change include Col4A2 (1.05x104 fold
change), MMP12 (‐7.37x106 fold change), and mTOR (‐2.22x103 fold change).
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Figure 2.7: MMP‐9 is Required for HGF‐induced Epithelial Cell Scattering, and MMP‐12 is
Required for HGF‐induced Cell Contraction Phase of Epithelial Cell Scattering. (A) MDCK time‐
lapse microscopy with HGF and Ilomastat (MMP‐9) reveals failure of HGF‐induced cell
scattering. (B) MDCK time‐lapse microscopy with HGF and Marimastat (MMP‐12) shows MMP‐
12 role in HGF‐induced cell contraction as a part of the cell scattering program. (C) MDCK cell
surface area changes over time.
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Figure 2.8: Furin Inhibition Blocks HGF‐induced EMT; Y‐Sec Inhibition is Cytotoxic. (A) MDCK cell
time‐lapse microscopy with HGF and Y‐Secretase inhibitor reveals quick cell death by as early as
6 hours after treatment. (B) MDCK cell time‐lapse microscopy with HGF and Darunavir (furin
inhibitor) reveals failure of epithelial cell scattering.
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Figure 2.9: BACE is Required for Early EMT Cell Spreading. (A) Time‐lapse live cell microscopy of
MDCK cells were filmed over 6 hrs after induced with HGF and/or BACE inhibitor. (B) MDCK cell
surface area chart illustrates the change in cell spreading/cell compaction during HGF induction.
(C) Changes in gene expression of Eph family genes and BACE family genes at different time
points after HGF induction.
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Figure 2.10: Model for Proteolytic Activity during Early EMT Events. A two‐phase
characterization of epithelial cell scattering includes cell spreading followed by cell contraction,
which is when cell‐cell contacts are broken. BACE activity is required for cell spreading to
progress, while MMP‐12 activity is required for cell contraction. Furin and MMP‐9 are both
required for cell scattering to progress, blocking both spreading and contraction phases. Y‐Sec
activity is required for cell survival and may not necessarily be involved in the c‐Met pathway.
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